Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6805495rdf:typepubmed:Citationlld:pubmed
pubmed-article:6805495lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:6805495lifeskim:mentionsumls-concept:C0442027lld:lifeskim
pubmed-article:6805495lifeskim:mentionsumls-concept:C0011615lld:lifeskim
pubmed-article:6805495lifeskim:mentionsumls-concept:C0012694lld:lifeskim
pubmed-article:6805495lifeskim:mentionsumls-concept:C2587213lld:lifeskim
pubmed-article:6805495pubmed:issue6lld:pubmed
pubmed-article:6805495pubmed:dateCreated1982-8-26lld:pubmed
pubmed-article:6805495pubmed:abstractTextA placebo-controlled double-blind crossover trial of oral sodium cromoglycate was undertaken in thirty children with atopic eczema, employing the dosage and administration schedule recommended by the manufacturers. No difference was detected between the effects of 4 weeks' treatment with sodium cromoglycate and placebo.lld:pubmed
pubmed-article:6805495pubmed:languageenglld:pubmed
pubmed-article:6805495pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6805495pubmed:citationSubsetIMlld:pubmed
pubmed-article:6805495pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6805495pubmed:statusMEDLINElld:pubmed
pubmed-article:6805495pubmed:monthJunlld:pubmed
pubmed-article:6805495pubmed:issn0007-0963lld:pubmed
pubmed-article:6805495pubmed:authorpubmed-author:SoothillJ FJFlld:pubmed
pubmed-article:6805495pubmed:authorpubmed-author:AthertonD JDJlld:pubmed
pubmed-article:6805495pubmed:authorpubmed-author:ElvidgeJJlld:pubmed
pubmed-article:6805495pubmed:issnTypePrintlld:pubmed
pubmed-article:6805495pubmed:volume106lld:pubmed
pubmed-article:6805495pubmed:ownerNLMlld:pubmed
pubmed-article:6805495pubmed:authorsCompleteYlld:pubmed
pubmed-article:6805495pubmed:pagination681-5lld:pubmed
pubmed-article:6805495pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:6805495pubmed:meshHeadingpubmed-meshheading:6805495-...lld:pubmed
pubmed-article:6805495pubmed:meshHeadingpubmed-meshheading:6805495-...lld:pubmed
pubmed-article:6805495pubmed:meshHeadingpubmed-meshheading:6805495-...lld:pubmed
pubmed-article:6805495pubmed:meshHeadingpubmed-meshheading:6805495-...lld:pubmed
pubmed-article:6805495pubmed:meshHeadingpubmed-meshheading:6805495-...lld:pubmed
pubmed-article:6805495pubmed:meshHeadingpubmed-meshheading:6805495-...lld:pubmed
pubmed-article:6805495pubmed:meshHeadingpubmed-meshheading:6805495-...lld:pubmed
pubmed-article:6805495pubmed:meshHeadingpubmed-meshheading:6805495-...lld:pubmed
pubmed-article:6805495pubmed:meshHeadingpubmed-meshheading:6805495-...lld:pubmed
pubmed-article:6805495pubmed:year1982lld:pubmed
pubmed-article:6805495pubmed:articleTitleA controlled trial of oral sodium cromoglycate in atopic eczema.lld:pubmed
pubmed-article:6805495pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6805495pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:6805495pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:6805495pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6805495lld:pubmed